This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
here is a vast clinical need for human serum albumin (HSA) with nearly 500 metric tons used worldwide every year.
Currently, HSA is isolated from donated human blood/plasma, a source that fluctuates unpredictably and can potentially
spread pathogens from donor to recipient. One solution to the problem is the use of transgenic cattle as living bioreactors,
enabling large-scale production of recombinant HSA (rHSA) in a cost-effective manner. Previous simple bovine transgenics
which express rHSA in the milk have not proved commercially viable due to the presence of endogenous bovine serum albumin
(BSA), resulting in a prohibitively expensive and tedious purification process. Ultimately, this project intends to provide proof-
of-principle for production of an inexpensive, reliable, and quality-controlled therapeutic source of rHSA through proposal of
the following: 1) Replace endogenous BSA expression with rHSA expression using transcription activator-like effector nuclease
(TALEN)-stimulated homologous recombination 2) Direct rHSA expression into the milk using a milk-specific alpha-lactalbumin
promoter 3) Produce transgenic bovine embryos from modified fibroblasts using somatic cell nuclear transfer (SCNT)
Shaida Moghaddassi is a Ph.D. candidate in the Molecular Genetics program at Wake Forest University and is completing her dissertation under
direction of Dr. Colin E. Bishop. She graduated with a B.S. in Biological Sciences from Clemson University in 2008
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals